Some of Wednesday's midday movers:» Read More
Several insurers, including Molina Healthcare, which administer health plans for California's Medicaid program for the poor are asking states to step in and pay for Gilead Sciences Inc's Sovaldi, a drug that costs $84,000 per patient.
CHICAGO, Dec 19- U.S. scientists have discovered the basic mechanisms that allow HIV to wipe out the body's immune system and cause AIDS, which could lead to new approaches to treatment and research for a cure for the disease that affects 35 million people around the world.
*Company to discuss approval expansion with FDA in early 2014. Dec 19- Vertex Pharmaceuticals Inc's Kalydeco cystic fibrosis drug failed to meet the main goal of a late-stage study aimed at expanding its use into patients with a specific gene mutation associated with the rare, life-threatening lung disease, the company said on Thursday.
Dec 19- Vertex Pharmaceuticals Inc said on Thursday that ivacaftor, an experimental drug to treat cystic fibrosis, failed to meet its targeted treatment goal in a late-stage study in people aged 6 and older with the "R117H" gene mutation. Shares fell to $64.20 in pre-market trading, a decline of 6.4 percent from a close of $68.63.
LONDON, Nov 22- European regulators have recommended approval of a new drug from Gilead Sciences to treat hepatitis C and an HIV medicine from GlaxoSmithKline, both of which are expected to be major sellers.
Oct 29- Vertex Pharmaceuticals Inc lowered its full-year revenue forecast and said it would cut about 15 percent of its workforce after sales of its hepatitis C drug plunged in the third quarter. The company's hepatitis C treatment, Incivek, was hugely popular when it was launched in May 2011 and revenue from the drug topped $1 billion in a few months.
Oct 29- Vertex Pharmaceuticals Inc lowered its full-year revenue forecast and said it would cut about 370 jobs after sales of its hepatitis C drug plunged in the third quarter. The company said it now expects full-year revenue in the range of $1 billion to $1.05 billion, down from its previous forecast of $1.1 billion to $1.2 billion.
Oct 22- A new hepatitis C drug made by Johnson& Johnson showed an acceptable safety profile in clinical trials, reviewers for the U.S. Food and Drug Administration said on Tuesday. J&J shares were up nearly 1 percent to $92 in morning trade on the New York Stock Exchange.
*BlackBerry shares fall further after change in focus. NEW YORK, Sept 23- U.S. stocks slipped on Monday as upbeat economic data from Germany and China was countered by a Federal Reserve official's remarks that the Fed could begin to scale back its stimulus measures this year.
*BlackBerry shares fall further after change in focus. NEW YORK, Sept 23- U.S. stocks were set to open mixed on Monday as traders balanced upbeat data from Germany and China with angst ahead of Federal Reserve speakers after last week's hawkish comments from a top Fed official.
*BlackBerry shares fall further after change in focus. NEW YORK, Sept 23- U.S. stock index futures were little changed in light volume on Monday following upbeat data from Germany and China, while Federal Reserve speakers could keep investors on edge after last week's hawkish comments from a top Fed official.
*Precious metal prices fall on Syria, worries Fed may scale back stimulus. NEW YORK, Sept 12- U.S. stocks slipped on Thursday, ending seven straight days of gains by the S&P 500 index as a drop in precious metal prices dragged mining shares lower.
NEW YORK, Sept 12- U.S. stocks edged lower on Thursday, on track to snap seven straight days of gains by the S&P 500 index, as a drop in precious metal prices dragged mining shares lower. The materials sector fell more than 1 percent, with gold miner Newmont Mining off 3.5 percent at $28.44.
**YAHOO INC, $30.03, up 3 pct. **ENDEAVOUR SILVER CORP, $4.31, down 7 pct. **BARRICK GOLD CORP, $17.81, down 4.4 pct.
NEW YORK, Sept 12- U.S. stocks fell in light volume on Thursday, snapping seven straight gains by the S&P 500 index, as an incomplete report on the U.S. jobs market left traders with little to guide them about next week's Federal Reserve meeting.
**ENDEAVOUR SILVER CORP, $4.31, down 7 pct. **BARRICK GOLD CORP, $17.81, down 4.4 pct. **MCEWEN MINING, $2.41, down 8 pct.
**ENDEAVOUR SILVER CORP, $4.31, down 7 pct. **BARRICK GOLD CORP, $17.81, down 4.4 pct. *MCEWEN MINING, $2.41, down 8 pct.
**OCLARO INC, $1.54, up 45 pct. The optical components maker, which has a market capitalization of about $98 million, said it sold its Zurich, Switzerland- based semiconductor laser business to II-VI Inc for about $115 million and its optical amplifier and micro-optics business for $88 million. **VERTEX PHARMACEUTICALS INC, $81.63, up 2 pct.
*Jobless claims fall more than expected, but data skewed. NEW YORK, Sept 12- U.S. stocks edged lower on Thursday after a seven-session winning streak on the S&P 500 and a jobless claims report which provided few clues into the Federal Reserve's upcoming decisions about stimulus policy.
**FACEBOOK INC, Wednesday close $45.04, up 1 pct premarket. Shares of Facebook rose more than 3 percent to a new high on Wednesday, valuing the world's No. 1 social network at $106 billion, as investors focused on its recent mobile advertising advances and the potential to expand ad revenue into new areas.